Format

Send to

Choose Destination
Future Microbiol. 2014;9(6):791-805. doi: 10.2217/fmb.14.32.

Antifungal drug discovery: the process and outcomes.

Author information

1
Georgetown University Medical Center, Washington, DC, USA.

Abstract

New data suggest that the global incidence of several types of fungal diseases have traditionally been under-documented. Of these, mortality caused by invasive fungal infections remains disturbingly high, equal to or exceeding deaths caused by drug-resistant tuberculosis and malaria. It is clear that basic research on new antifungal drugs, vaccines and diagnostic tools is needed. In this review, we focus upon antifungal drug discovery including in vitro assays, compound libraries and approaches to target identification. Genome mining has made it possible to identify fungal-specific targets; however, new compounds to these targets are apparently not in the antimicrobial pipeline. We suggest that 'repurposing' compounds (off patent) might be a more immediate starting point. Furthermore, we examine the dogma on antifungal discovery and suggest that a major thrust in technologies such as structural biology, homology modeling and virtual imaging is needed to drive discovery.

KEYWORDS:

antifungals; compound libraries; discovery; drug targets; repurposing

PMID:
25046525
PMCID:
PMC4144029
DOI:
10.2217/fmb.14.32
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center